Skip to main content
AAN.com
Research Article
May 10, 2024

Irish Amyotrophic Lateral Sclerosis Incidence
Age, Period, and Cohort Effects Using a Partial Least Squares Regression Model

Abstract

Background and Objectives

To investigate the underlying reasons for variability in the incidence rate of amyotrophic lateral sclerosis (ALS) within the Irish population between the years 1996 and 2021.

Methods

The Irish ALS register was used to calculate the incidence and to subsequently extract age at diagnosis (age), year of diagnosis (period), and date of birth (cohort) for all incident patients within the study period (n = 2,771). An age-period-cohort (APC) model using partial least squares regression was constructed to examine each component separately and their respective contribution to the incidence while minimizing the well-known identifiability problem of APC effects. A dummy regression model consisting of 5 periods, 19 cohorts, and 16 age groups was used to examine nonlinear relationships within the data over time. The CIs for each of these were estimated using the jackknife method.

Results

The nonlinear model achieved R2 of 99.43% with 2-component extraction. Age variation was evident with those in the ages 65–79 years contributing significantly to the incidence (βmax = 0.0746, SE = 0.000410, CI 0.00665–0.00826). However, those aged 25–60 years contributed significantly less (βmin = −0.00393, SE = 0.000291, CI −0.00454 to −0.00340). Each successive period showed an increase in the regression model coefficient suggesting an increasing incidence over time, independent of the other factors examined—an increase of β from −0.00489 (SE = 0.000264, CI −0.00541 to −0.00437) to 0.00973 (SE = 0.000418, CI 0.0105–0.00891). A cohort effect was demonstrated showing that the contribution of those born between 1927 and 1951 contributed to a significantly greater degree than the other birth cohorts (βmax = 0.00577, SE = 0.000432, CI 0.00493–0.00662).

Discussion

Using the Irish population-based ALS Register, robust age, period, and cohort effects can be identified. The age effect may be accounted for by demographic shifts within the population. Changes in disease categorization, competing risks of death, and improved surveillance may account for period effects. The cohort effect may reflect lifestyle and environmental factors associated with the challenging economic circumstances in Ireland between 1927 and 1951. Age-period-cohort studies can help to account for changes in disease incidence and prevalence, providing additional insights into likely demographic and environmental factors that influence population-based disease risk.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Incidence and prevalence of ALS in Ireland, 1995-1997: a population-based study. Neurology. 1999;52(3):504-509.
2.
O'Toole O, Traynor BJ, Brennan P, et al. Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004. J Neurol Neurosurg Psychiatry. 2008;79(1):30-32.
3.
Seals RM, Hansen J, Gredal O, Weisskopf MG. Age-period-cohort analysis of trends in amyotrophic lateral sclerosis in Denmark, 1970-2009. Am J Epidemiol. 2013;178(8):1265-1271.
4.
Tobin K, Gilthorpe MS, Rooney J, et al. Age-period-cohort analysis of trends in amyotrophic lateral sclerosis incidence. J Neurol. 2016;263(10):1919-1926.
5.
Gordon PH, Artaud F, Aouba A, Laurent F, Meininger V, Elbaz A. Changing mortality for motor neuron disease in France (1968-2007): an age-period-cohort analysis. Eur J Epidemiol. 2011;26(9):729-737.
6.
Nakken O, Lindstrøm JC, Tysnes O-B, Holmøy T. Mortality trends of amyotrophic lateral sclerosis in Norway 1951-2014: an age-period-cohort study. J Neurol. 2016;263(12):2378-2385.
7.
Rooney J, Vajda A, Heverin M, et al. Spatial cluster analysis of population amyotrophic lateral sclerosis risk in Ireland. Neurology. 2015;84(15):1537-1544.
8.
Ireland Central Statistics Office of Ireland. 2024. Accessed Feburary 1, 2024. cso.ie.
9.
Tu YK, Krämer N, Lee WC. Addressing the identification problem in age-period-cohort analysis: a tutorial on the use of partial least squares and principal components analysis. Epidemiology. 2012;23(4):583-593.
10.
R Core Development Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2022.
11.
Liland KH, Mevik BH, Wehrens R. pls: Partial Least Squares and Principal Component Regression. 2022.
12.
McFarlane R, Peelo C, Galvin M, Heverin M, Hardiman O. Epidemiologic trends of amyotrophic lateral sclerosis in Ireland, 1996-2021. Neurology. 2023;101(19):e1905-e1912.
13.
Haenlein M, Kaplan AM. A beginner's guide to partial least squares analysis. Understand Stat. 2004;3(4):283-297.
14.
Chiò A, Mora G, Moglia C, et al; Piemonte and Valle d'Aosta Register for ALS PARALS. Secular trends of amyotrophic lateral sclerosis: the Piemonte and Valle d'Aosta Register. JAMA Neurol. 2017;74(9):1097-1104.
15.
Ajdacic-Gross V, Schmid M, Tschopp A, Gutzwiller F. Birth cohort effects in neurological diseases: amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. Neuroepidemiology. 2012;38(1):56-63.
16.
Al-Chalabi A, Calvo A, Chio A, et al. Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13(11):1108-1113.

Information & Authors

Information

Published In

Neurology®
Volume 102Number 11June 11, 2024
PubMed: 38728654

Publication History

Received: September 26, 2023
Accepted: February 22, 2024
Published online: May 10, 2024
Published in print: June 11, 2024

Permissions

Request permissions for this article.

Disclosure

R. McFarlane, M. Heverin, and C. Walsh report no disclosures relevant to the manuscript. O. Hardiman has served on advisory boards for Biogen, Orion Pharma, Novartis, Amylyx, Cytokinetics, Accelsior, Neuroscense, and Sanofi. She has received speakers fees from Biogen, Novartis, Lundbeck, Cytokinetics, and Apellis. She is an investigator in clinical trials sponsored by Biogen, Cytokinetics, Ferrer, Amylyx, Corcept therapeutics, IONIS Pharmaceuticals, Apellis Pharmaceuticals, Alexion Pharmaceuticals, and Orion Pharma. She is a Lead Investigator on an Academic/Industry partnership PRECISION ALS. She is an Editor-in-Chief of the journal ALS and the Frontotemporal Degenerations. Go to Neurology.org/N for full disclosures.

Study Funding

This study was supported by a grant from the Science Foundation Ireland (grant 20SP8953) and by grants from the Irish Health Research Board and the Charity research Motor Neuron.

Authors

Affiliations & Disclosures

From the Academic Unit of Neurology (R.M., M.H., O.H.), and Department of Biostatistics (C.W.), Trinity College Dublin, Ireland.
Disclosure
Financial Disclosure:
1.
NONE
Research Support:
1.
NONE
Stock, Stock Options & Royalties:
1.
NONE
Legal Proceedings:
1.
NONE
From the Academic Unit of Neurology (R.M., M.H., O.H.), and Department of Biostatistics (C.W.), Trinity College Dublin, Ireland.
Disclosure
Financial Disclosure:
1.
NONE
Research Support:
1.
NONE
Stock, Stock Options & Royalties:
1.
NONE
Legal Proceedings:
1.
NONE
From the Academic Unit of Neurology (R.M., M.H., O.H.), and Department of Biostatistics (C.W.), Trinity College Dublin, Ireland.
Disclosure
Financial Disclosure:
1.
NONE
Research Support:
1.
NONE
Stock, Stock Options & Royalties:
1.
NONE
Legal Proceedings:
1.
NONE
From the Academic Unit of Neurology (R.M., M.H., O.H.), and Department of Biostatistics (C.W.), Trinity College Dublin, Ireland.
Disclosure
Financial Disclosure:
1.
Personal Compensation: (1) Scientific Advisory Board - Biogen (2) Scientific Advisory Board - Novartis (3) Scientific Advisory Board - Cytokinetics (4) Scientific Advisory Board - Denali (5) Scientific Advisory Board - Neurosense (6) Data Safety Monitoring Board - Accelsiors (7) Speaker Honorarium - Biogen (8) Speaker Honorarium - Novartis (9) Speaker Honorarium - Cytokinetics (10) Editor in Chief - Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
Research Support:
1.
(1) Government - Science Foundation Ireland (PRECISION ALS ): Development of a Pan European Patient Data Platform (academic industry collaboration
Stock, Stock Options & Royalties:
1.
NONE
Legal Proceedings:
1.
NONE

Notes

Correspondence Dr. McFarlane [email protected]
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Submitted and externally peer reviewed. The handling editor was Associate Editor Anthony Amato, MD, FAAN.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Temporo-spatial analysis of amyotrophic lateral sclerosis in Spain: Altitude and land use as new determinants of the disease, Science of The Total Environment, 957, (177796), (2024).https://doi.org/10.1016/j.scitotenv.2024.177796
    Crossref
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Short Form

Short Form

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Figures

Tables

Media

Share

Share

Share article link

Share